Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has temporarily halted recruitment and dosing in three clinical studies of its ...

Sarepta stock plunged Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold.

A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...

Sarepta and Roche announced a 16-year-old US patient dosed with Elevidys died of acute liver failure in March 2025.

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety ...

One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the ...

Shares of Sarepta, based in Cambridge, Massachusetts, dropped more than 27% on Tuesday, closing at about $73 per share. Elevidys, which costs $3.2 million for a one-time infusion, was the first gene ...

Multidisciplinary coordination across prescribing teams, nursing, laboratory medicine, finance, and infusion centers is crucial for gene therapy delivery in Duchenne muscular dystrophy (DMD).

In other recent news, Sarepta Therapeutics has been the focus of several analyst updates and regulatory developments concerning its gene therapy, ELEVIDYS, for Duchenne muscular dystrophy (DMD).

Sarepta Therapeutics and Roche are looking to get approval to continue clinical trials of their Duchenne muscular dystrophy gene therapy Elevidys (delandistrogene moxeparvovec-rokl) following a ...

In other recent news, Sarepta Therapeutics has been the focus of several analyst updates and regulatory developments concerning its gene therapy, ELEVIDYS, for Duchenne muscular dystrophy (DMD). Wells ...